Transcode Therapeutics Inc (RNAZ) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $9.98
• Market Cap: $9.15M
• EPS: $-236.52
• 52-Week High: $71.12
• 52-Week Low: $6.08

Market Sentiment

Transcode Therapeutics Inc currently has a Bullish sentiment score of 0.31.

About Transcode Therapeutics Inc

TransCode Therapeutics, Inc. (RNAZ) is an innovative biopharmaceutical company focused on advancing the treatment of metastatic diseases through the development and commercialization of novel therapeutic agents. Headquartered in Boston, Massachusetts, TransCode is leveraging its proprietary technologies to address significant unmet medical needs in oncology, with an emphasis on enhancing the effectiveness of cancer treatments. The company's commitment to transforming cancer care positions it ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Transcode Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does RNAZ pay dividends?

Transcode Therapeutics Inc (RNAZ) does not currently pay a regular dividend.

What is RNAZ's market cap?

Transcode Therapeutics Inc (RNAZ) has a market capitalization of $9.15M with a current stock price of $9.98.